Translate
Verastem, Inc.
About
4.30USD-0.07 -1.49%
Closed • Updated at 15:51 GMT+00:00Market Cap$377.42M
Volume857.1K
Beta0.89
RSI34.00
Gross Margin82.91%
Verastem, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Yesterday
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
May 7 2026
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Apr 30 2026
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Apr 23 2026
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
Apr 10 2026
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers
Recent Videos
Verastem Oncology Update: RAMP 203 Phase 1/2 Clinical Trial for KRAS G12C NSCLC
May 11, 2026
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of...
Apr 30, 2026
Verastem Oncology (VSTM|$388.6M) - 2025 Q4 & Full Year Earnings Analysis
Mar 05, 2026
Verastem's 8-K: My Take on Their Financials & Strategy
Feb 05, 2026
Community Chat
Ask AI
Try asking